• Eurofarma posted 2Q26 net revenue of R$ 3.12 billion, up 14.8% from 2Q25.
• EBITDA more than doubled to R$ 601.3 million, lifting the EBITDA margin to 19.3% from 11.1%.
• Net income swung to a profit of R$ 159.8 million from a loss a year earlier.
• Free cash flow climbed 73.6% to R$ 642.5 million; net debt/EBITDA narrowed to 2.66x from 3.70x.
• Eurofarma expects XCOPRI (cenobamate) in Brazil pharmacies from August 2026 after CMED pricing in July; it filed a chikungunya vaccine with Anvisa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurofarma Laboratorios SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.